Want to see HK:0512 full AI Analyst Report?
0512 Stock Chart & Stats
HK$5.32
-HK$0.06(-1.03%)
At close: 4:00 PM EDT
HK$5.32
-HK$0.06(-1.03%)
Day’s Range― - ―
52-Week RangeHK$4.53 - HK$9.64
Previous CloseN/A
Volume767.50K
Average Volume (3M)9.26M
Market Cap
HK$18.60B
Enterprise ValueHK$20.34K
Total Cash (Recent Filing)HK$2.09B
Total Debt (Recent Filing)HK$4.72B
Price to Earnings (P/E)16.3
Beta0.72
Next Earnings
Mar 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.23%
Share Statistics
EPS (TTM)0.35
Shares Outstanding3,549,571,000
10 Day Avg. Volume7,622,050
30 Day Avg. Volume9,255,379
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.62
Price to Sales (P/S)2.24
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.68
Revenue Forecast (FY)HK$13.44B
Bulls Say, Bears Say
Bulls Say
Resilient Revenue GrowthConsistent revenue expansion indicates resilient underlying demand across the company’s pharmaceutical and medical-device portfolio, supporting a durable base for future growth even as profitability has weakened.
Moderate Balance-Sheet LeverageModerate and stable leverage limits balance-sheet risk and preserves financial flexibility for research, manufacturing capacity, commercialization and other investments needed to support longer-term growth.
Diversified Healthcare PlatformExposure to multiple pharmaceutical segments, medical devices and healthcare distribution channels reduces dependence on one product or customer group and can support more durable market access over time.
Bears Say
Material Margin CompressionThe sharp decline in operating and net margins signals weaker earnings quality and may reflect persistent cost, pricing or product-mix pressure, reducing the profitability of otherwise stable revenue growth.
Weaker Cash ConversionLower operating cash flow and reduced free-cash-flow conversion weaken internally generated funding for research, expansion and shareholder returns, while raising the risk that investment needs outpace cash generation.
Reduced Earnings PowerThe steep EPS decline and lower return on equity show that the business is currently generating less profit from its capital base, which could constrain reinvestment capacity and weaken long-term returns if not reversed.
Grand Pharmaceutical Group Limited News
0512 FAQ
What was Grand Pharmaceutical Group Limited’s price range in the past 12 months?
Grand Pharmaceutical Group Limited lowest stock price was HK$4.53 and its highest was HK$9.64 in the past 12 months.
What is Grand Pharmaceutical Group Limited’s market cap?
Grand Pharmaceutical Group Limited’s market cap is HK$18.60B.
When is Grand Pharmaceutical Group Limited’s upcoming earnings report date?
Grand Pharmaceutical Group Limited’s upcoming earnings report date is Mar 17, 2027 which is in 199 days.
How were Grand Pharmaceutical Group Limited’s earnings last quarter?
Grand Pharmaceutical Group Limited released its earnings results on Aug 26, 2026. The company reported HK$0.278 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Grand Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Grand Pharmaceutical Group Limited’s price is currently Overvalued.
Does Grand Pharmaceutical Group Limited pay dividends?
Grand Pharmaceutical Group Limited pays a Annually dividend of HK$0.169 which represents an annual dividend yield of 3.23%. See more information on Grand Pharmaceutical Group Limited dividends here
What is Grand Pharmaceutical Group Limited’s EPS estimate?
Grand Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grand Pharmaceutical Group Limited have?
Grand Pharmaceutical Group Limited has 3,549,571,000 shares outstanding.
What happened to Grand Pharmaceutical Group Limited’s price movement after its last earnings report?
Grand Pharmaceutical Group Limited reported an EPS of HK$0.278 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.379%.
Which hedge fund is a major shareholder of Grand Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:0512
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grand Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.42%
12-Months-Change
Fundamentals
Return on Equity
3.23%
Trailing 12-Months
Asset Growth
8.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―